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Abstract
The objective of the current study was to characterize the profile of oral metabolites in HIV-infected patients
using metabolomics. Oral wash samples were collected from 12 HIV-infected and 12 healthy individuals
(matched for age, sex, and ethnicity), processed, and analyzed by metabolomics. We detected 198 identifiable
and 85 nonidentifiable metabolites; 27 identifiable metabolites were differentially present (12 increased, 15
decreased) in HIV-infected patients. Elevated metabolites included p-cresol sulfate, nucleotides (e.g., allantoin),
and amino acids (e.g., phenylalanine, tryptophan), whereas decreased oral metabolites included fucose, fuma-
rate, and N-acetylglucosamine. Pathway network analysis revealed the largest multinode network in healthy
versus HIV-infected patients to involve carbohydrate biosynthesis and degradation. HIV-infected patients on
antiretroviral therapy (ART) showed the largest number (12) of statistically significant metabolite correlation
differences compared with healthy controls. Interestingly, the oral phenlyalanine:tyrosine ratio increased in ART-
naive HIV-infected patients (mean SEM¼ 2.58 0.87) compared with healthy individuals (1.33 0.10, p¼ 0.062)
or ART-experienced patients (1.78 0.30, p¼ 0.441). This is the first study to reveal differential levels of oral
metabolites in HIV-infected patients compared withj healthy volunteers, and that oral phenlyalanine:tyrosine ratio
may be a useful marker for noninvasive monitoring of the immune status during HIV infection.
Introduction
The oral cavity plays an important role in providinginsight into the status/progression of HIV disease as the
occurrence of specific lesions, mainly oral candidiasis and
hairy leukoplakia (Patton et al., 2002; Shiboski et al., 2009).
With recent advances in high-throughput technologies, it has
been suggested that ‘‘-omics’’ disciplines, such as metabo-
lomics and proteomics, should be applied to reach a deeper
understanding of the molecular mechanisms underlying oral
disorders (Garcia and Tabak, 2008). Metabolites (small mol-
ecules including amino acids, sugars and lipids) present in the
oral cavity are produced by both the host and microbes, and
are likely to contribute to health and disease (Pendyala et al.,
2007; Sreekumar et al., 2009; Sugimoto et al., 2010). Similar to
the oral lesions, oral metabolites may also have utility in in-
forming about disease status and/or treatment compliance by
acting as diagnostic markers. Thus, profiling the oral metab-
olites is a prerequisite to defining the mechanisms underlying
oral diseases in HIV-infected patients and the discovery of
diagnostic targets.
Metabolomics is increasingly being used to accurately
measure the spectrum of biochemical changes and map them to
metabolic pathways, and has utility in the discovery of disease
biomarkers and drug targets. For example, metabolomics has
been used to characterize the metabolites present in cancer
patients (Denkert et al., 2006, 2008; Sreekumar et al., 2009; Yan
et al., 2008), and several studies have suggested associations
between different metabolites and cancer Recent studies have
also investigated the link between metabolites and oral cancer,
where investigators used this approach to identify profiles
specific to oral, breast, pancreatic, and oral squamous cell car-
cinoma (Sugimoto et al., 2010; Zhou et al., 2009).
The progresses in oral pathologies using purely genomic
approaches have been overall limited (Diehl, 2006). To date,
no study has been performed to characterize oral metabolites
in the background of HIV infection, and to determine whether
specific metabolites correlate with HIV disease progression
and response to antiretroviral therapy (ART). In the current
study, to gain insight into oral metabolites and their associa-
tion with HIV disease, we used metabolomics to compare the
oral metabolome in healthy subjects and participants with
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HIV infection. Analysis of oral wash samples showed differ-
ential levels of metabolites in HIV-infected patients compared
with healthy subjects, including those involved in amino acid
and carbohydrate metabolic pathways.
Materials and Methods
Ethical conduct of research statement
Written informed consent was obtained from all partici-
pants in this study. Recruitment of study participants was
performed according to protocol (#20070413) approved by the
Human Subjects Institution Review Board (IRB) of Case
Western Reserve University, Cleveland (OH), and UH/Case
Medical Center CFAR, Cleveland (OH).
Study participants
Oral rinse samples were collected from 12 healthy indi-
viduals and 12 HIV-positive patients, age, gender, and self-
reported ethnicity matched. Informed consent was obtained
following review of the IRB at Case Western Reserve Uni-
versity/University Hospitals Case Medical Center. The sub-
jects were all from the Cleveland Ohio area and on standard
Western diets. The healthy controls were recruited from stu-
dents and staff at the School of Dental Medicine, or School of
Medicine at Case Western Reserve University (CWRU). HIV-
positive subjects were recruited from the University Hospitals
Case Medical Center, Center for AIDS Research unit (CFAR)
and were patients of record in the CFAR unit.
Summary of demographic information of subjects enrolled
in the study is provided in Table 1. Self-reported ethnicities of
the study participants were classified based upon U.S. Census
criteria for classification of race (http://www.census.gov).
Race has been classified as White (including Hispanic, East
Indian, or European), Black/African American, Asian, and
Native American/Native Alaskan, etc. Current antiretroviral
medications, most recent viral load and CD4 counts and
smoking status, in addition to age, gender, and ethnicity were
collected from HIV-infected participants.
Inclusion criteria were age greater than 18 years, and no
clinical signs of oral mucosal disease. Exclusion criteria were
recent use of antimicrobial or antifungal agents, use of topical
or systemic steroids, pregnancy, and insulin-dependent dia-
betes mellitus.
Sample collection
Concentrated oral rinse has been previously used for the
detection of the presence of oral bacteria and fungi (Sedgley
and Samaranayake, 1994; White et al., 2004; Yan et al., 2008).
Oral rinse (10 mL 0.9% sterile saline) was utilized for this
study because (1) it’s simple and noninvasive to collect; (2) it’s
safe to handle compared to other body fluids (blood); (3) its
oral cavity is a primary entry point for microbes into the body;
(4) oral rinse provides a better representation of the oral
chamber environment, and enables the collection of organ-
isms from the dorsum of the tongue, floor of the mouth, pal-
ate, posterior pharynx, and buccal mucosal environment; (5) it











1C Healthy — 34 M H (W) NA NA None
2C Healthy — 46 M C (W) NA NA None
3C Healthy — 59 M AA NA NA None
4C Healthy — 22 M C (W) NA NA None
5C Healthy — 37 M AA NA NA None
6C Healthy — 34 F H (W) NA NA None
7C Healthy — 40 M C (W) NA NA None
8C Healthy — 27 M C (W) NA NA None
9C Healthy — 53 M AA NA NA None
10C Healthy — 44 M AA NA NA None
11C Healthy — 22 M AA NA NA None
12C Healthy — 47 M AA NA NA None
ART-experienced HIV-infected patients
2 HIV-infected ART-experienced 56 M AA 639 75 Atripla
3 HIV-infected ART-experienced 52 M AA 800 48 Atripla
4 HIV-infected ART-experienced 40 M C (W) 947 48 Atripla
5 HIV-infected ART-experienced 40 M C (W) 280 48 Atripla
7 HIV-infected ART-experienced 31 F H (W) 1,029 48 Ritonavir, Fosamprenavir,
Combivir
8 HIV-infected ART-experienced 42 M AA 814 53 Ritonavir, Atazanavir, Truvada
11 HIV-infected ART-experienced 31 M C (W) 670 68 Atripla
12 HIV-infected ART-experienced 45 M AA 899 48 Ritonavir, Atazanavir, Truvada
ART-naive HIV-infected patients
1 HIV-infected ART-naive 31 M H (W) 380 158,000 None
6 HIV-infected ART-naive 22 M AA 966 1,100 None
9 HIV-infected ART-naive 22 M C (W) 581 115,000 None
10 HIV-infected ART-naive 52 M AA 5 185,000 None
ART, antiretroviral therapy; W, White; H, Hispanic; C, Caucasian; AA, African-American.
6 GHANNOUM ET AL.
facilitates collection of oral chamber metabolites. Oral sam-
ples were collected at least 1 h after a meal, at approximately
the same time for all participants (9–11 a.m.). This was done to
limit contamination of samples with extraneous components
and standardize the possible impact of variation in salivary
flow rates. Study participants were provided a 10-mL syringe
with 0.9% sterile normal saline. The subjects were instructed
to inject the contents into their mouth and swish for 1 min,
after which time were to expectorate into a sterile 50-mL
conical tube. Samples were then stored on ice until it was
transported back to the lab for processing (within 2 h). The
collected samples were then centrifuged at 3,500g for 20 min
at 48C to separate the cells (pellet) from the extra cellular
soluble components (supernatant). The supernatant extracted
with acetonitrile and processed for metabolome analysis (as
described below). Each sample received was accessioned into
the Laboratory Information Management System (LIMS) at
Metabolon and was assigned a unique identifier, and bar
coded. The unique identifier and bar codes were used to track
all samples (and all derived aliquots), tasks, and results. All
samples were maintained at 808C until processed.
Sample processing
The sample preparation process was carried out using the
automated MicroLab STAR system (Hamilton Company,
Reno, NV), as described earlier (Cantor, 2010; Dehaven et al.,
2010; Evans et al., 2009; Ohta et al., 2009; Takei et al., 2010).
Recovery standards were added prior to the first step in the
extraction process for quality control (QC) purposes. Sample
preparation was conducted using a series of organic and
aqueous extractions to remove the protein fraction while
allowing maximum recovery of small molecules. The result-
ing extract was divided into two fractions: one for analysis by
liquid chromatography (LC) and the second for analysis by
gas chromatography (GC). Samples were placed briefly on a
TurboVap (Zymark) to remove the residual organic solvent.
Each sample was then frozen and dried under vacuum, and
prepared for LC/mass spectrometry (MS) or GC/MS. A small
aliquot of each experimental sample for a specific matrix was
obtained and pooled together as a ‘‘Client matrix’’ (CMTRX).
Aliquots of these CMTRX samples were injected throughout
the platform day run and serve as technical replicates. Such
analysis allows monitoring of variability in the quantitation of
the detected biochemicals in the experimental samples. With
this monitoring, a metric for overall process variability can be
assigned for the platform’s performance based on the quan-
titation of metabolites in the actual experimental samples.
LC/MS, LC/MS2
The LC/MS portion of the platform is based on a Waters
Acquity UPLC and a Thermo-Finnigan LTQ mass spectrom-
eter, which consists of an electrospray ionization (ESI) source
and linear ion-trap (LIT) mass analyzer. The sample extract
was split into two aliquots, dried, then reconstituted in acidic
or basic LC-compatible solvents, each of which contain 11 or
more injection standards at fixed concentrations. One aliquot
was analyzed using acidic positive ion optimized conditions
and the other using basic negative ion optimized conditions in
two independent injections using separate dedicated col-
umns. Extracts reconstituted in acidic conditions were gra-
dient eluted using water and methanol both containing 0.1%
formic acid, while the basic extracts, which also used water/
methanol, contained 6.5 mM ammonium bicarbonate. The MS
analysis alternates between MS and data-dependent MS2
scans using dynamic exclusion.
Accurate mass determination and MS/MS
fragmentation (LC/MS), (LC/MS/MS)
The LC/MS accurate mass portion of the platform was
based on a Waters Acquity UPLC and a Thermo-Finnigan
LTQ-FT mass spectrometer, which has a linear ion-trap (LIT)
front end and a Fourier transform ion cyclotron resonance
(FT-ICR) mass spectrometer backend. For ions with counts
greater than 2 million, an accurate mass measurement can be
performed. Accurate mass measurements can be made on the
parent ion as well as fragments. The typical mass error is less
than 5 ppm. Ions with less than 2 million counts require a
greater amount of effort to characterize. Fragmentation
spectra (MS/MS) are typically generated in data-dependent
manner, but if necessary, targeted MS/MS can be employed,
such as in the case of lower level signals.
GC/MS
The samples destined for GC/MS analysis were redried
under vacuum desiccation for a minimum of 24 h prior to
being derivatized under dried nitrogen using bistrimethyl-
silyl-triflouroacetamide (BSTFA). The GC column used was
5% phenyl and the temperature ramp was from 408 to 3008C
in a 16-min period. Samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass
spectrometer using electron impact ionization. The instru-
ment was tuned and calibrated for mass resolution and mass
accuracy on a daily basis. The information output from the
raw data files were automatically extracted as discussed be-
low.
Bioinformatics
The informatics system consisted of four major compo-
nents, the Laboratory Information Management System
(LIMS), the data extraction and peak-identification software,
data processing tools for QC and compound identification,
and a collection of information interpretation and visualiza-
tion tools for use by data analysts. The hardware and software
foundations for these informatics components were the LAN
backbone, and a database server running Oracle 10.2.0.1 En-
terprise Edition.
Compound identification
Biochemicals were identified by comparison to library en-
tries of purified standards or recurrent unknown entities.
Identification of known chemical entities was based on com-
parison to metabolomic library entries of purified standards.
Approximately 1,500 commercially available purified stan-
dard biochemicals have been acquired and registered into
LIMS for distribution to both the LC and GC platforms, for
determination of their analytical characteristics. The combi-
nation of chromatographic properties and mass spectra give
an indication of a match to the specific compound or an iso-
baric entity. Additional chemical entities can be identified by
virtue of their recurrent nature (both chromatographic and
mass spectral). These biochemicals have the potential to be
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identified by future acquisition of a matching purified stan-
dard or by classical structural analysis.
Curation
A variety of curation procedures were carried out to ensure
that a high-quality data set was made available for statistical
analysis and data interpretation. The QC and curation pro-
cesses were designed to ensure accurate and consistent
identification of true chemical entities, and to remove those
representing system artifacts, mis-assignments, and back-
ground noise. Library matches for each compound were
checked for each sample and corrected if necessary.
Normalization
For studies spanning multiple days, a data normalization
step was performed to correct variation resulting from instru-
ment interday tuning differences. Essentially, each compound
was corrected in run-day blocks by registering the medians to
equal one (1.00) and normalizing each data point proportio-
nately (termed the ‘‘block correction’’). For studies that do not
require more than 1 day of analysis, no normalization was
necessary, other than for purposes of data visualization.
Differential correlation network (DCN)
Performing DCN analysis allows sifting through large
volumes of data and focuses on potentially significant rela-
tionships between metabolites and enhances the ability to
interpret a complex oral environment (Giacomelli and Covani,
2010). This technique supports knowledge discovery and
hypotheses generation by extracting significantly different
correlations between same metabolite pairs in class 1 versus
class 2. The data generated in our study were comprised of
three classes (metabolome variants): (1) healthy controls, (2)
HIV-infected (ART-naive and -experienced), and (3) ART-
experienced HIV-infected patients. One hundred ninety-eight
known metabolites were measured for each sample in each
class. First, each class was analyzed internally for significant
metabolite pair correlations using the Spearman Rank corre-
lation (we chose Spearman correlation for this analysis to
address issues with small sample sizes, and the inability to
assume parametric data). Next, metabolite pair correlations
within each class were assessed to determine if there is a
significant difference in the pair’s correlation across classes.
The significance of the correlation differential was determined
using the z-value statistic (Morgenthal et al., 2006), then
converted to a significance probability. Because there were
only 12 patients in each group, significant differences were
concluded based on the relaxed statistical cutoff of p< 0.2
(using Wilcoxon Rank Sum Test) (Sreekumar et al., 2009). All
metabolite data were included in the correlation analysis.
Determination of a metabolite pair correlation required three
samples in the same class, with measureable values for both of
the sample metabolites. The metabolites (nodes) were color
coded by their KEGG superpathway; edges reflecting differ-
ential correlations between metabolite nodes are either red, if
the correlation differential network for the healthy versus the
HIV experienced classes, or green, for the DCN for the healthy
versus the All-HIV class. The edge labels indicate the signifi-
cance probability associated with the correlation differential
determined above.
Results
Oral metabolites are differentially produced
in HIV infection
A prerequisite to understanding the effect of oral metabo-
lites on initiation and progression of HIV disease is to define
their profile in HIV-infected patients compared with healthy
individuals. Therefore, we compared the metabolite profile of
oral wash samples obtained from 12 HIV-infected and 12
healthy individuals matched for gender (92% males, 8% fe-
males), ethnicity (Hispanic, 17%; African-American, 50%;
Caucasian, 33%), and age (mean age 39 years) (see Table 1 for
participant demographics). The metabolomic data generated
for the two groups (healthy and HIV-infected) were compared
by the nonparametric Wilcoxon Rank Sum Test, following log
transformation and imputation with minimum observed
values for each compound. Our results showed the presence
of 198 identifiable and 85 nonidentifiable metabolites. Among
the identifiable metabolites, 27 were differentially present (12
increased, mainly amino acids; 15 decreased, mainly carbo-
hydrates) in HIV-infected patients (Table 2, and supporting
Supplementary Table ST1). Metabolites with elevated levels
included p-cresol sulfate, nucleotides (e.g., allantoin, thymine,
AMP), amino acids (e.g., Trp, Phe, Tyr) and the tyrosine-
derivative tyramine. Metabolites with decreased levels
in HIV-infected patients included fucose, fumarate, and
N-acetylglucosamine. Some of the differentially present
metabolites (e.g., p-cresol sulfate, tyramine, allantoin) are
known to be associated with microbial activity.
DCN analysis revealed differences in metabolic
pathways between healthy individuals
and HIV-infected patients
To obtain a biological process perspective of the metabo-
lites in the oral cavity of healthy and HIV-infected patients,
we performed DCN analysis on the data using Python-based
Spearman correlation algorithm, and the resulting networks
were visualized with the open source Cytoscape Network
visualization package (www.cytoscape.org) (Cline et al.,
2007; Shannon et al., 2003), with the Metscape plug-in (Gao
et al., 2010). Our analyses revealed interconnected nodes
spanning across several metabolic superpathways, with some
metabolites (e.g., taurine) presenting a large number of con-
nections to other metabolites (Fig. 1; see supporting Supple-
mentary Figs. SF1 and SF2 and supporting Supplementary
Table ST2 for list of KEGG IDs used to generate the network
pathways). Several smaller sets of interconnected nodes were
also detected, demonstrating increased or decreased metab-
olism in the amino acid and nucleotide superpathways.
Correlation differences were calculated for two groups: (1)
healthy versus ART–experienced HIV-infected patients (red
edges, Fig. 2A), and (2) healthy versus HIV-infected (includ-
ing ART-naive and -experienced) patients (green edges, Fig.
2B). Our results showed that the largest cluster of statistically
significant metabolite correlation differences detected for
Group A involves six metabolites (indicating significantly
differentiated metabolism in ART-experienced patients
compared with healthy individuals), of which five metabo-
lites were those involved in amino acid and nucleotide
superpathways (Fig. 2A). In contrast, for Group B, the
largest multinode cluster of the DCN involved differential
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correlations between seven metabolites based on the KEGG
superpathways; for xenobiotics, plus cofactors and vitamins.
Other smaller sets of interconnected nodes were also ob-
served, where increased and decreased metabolism in the
amino acid and nucleotide superpathways were noted.
Overall, 42 significant interactions between metabolite pairs
were observed in Group A (healthy versus ART-experienced
HIV-infected patients), whereas 18 interactions were detected
for metabolite pairs in Group B (healthy versus all HIV-
infected patients) (Fig. 2C). Interestingly, four interac-
tions were common to both groups, albeit with differing
significance probabilities; these four metabolite pairs were:
valerate–4-hydroxyphenylpyruvate, 4-hydroxyphenylpyruvate–
isocaproate, isocaproate–caproate, and 1-kestose–sucrose.
These results showed specific changes in metabolic profile
between healthy and HIV-infected patients.
Association between metabolite levels and ART status
We found significant increase in the levels of 17 metabolites
in ART-naive patients compared to ART-experienced patients
(Table 3, p< 0.05). These elevated metabolites included as-
partate, phenylacetate, indole acetate, and sarcosine. Inter-
estingly, levels of tyramine exhibited a reverse pattern,
being decreased in ART-naive patients compared with ART-
experienced HV-infected patients. In addition, among HIV-
infected patients, levels of 23 metabolites were positively
correlated with viral load with a correlation coefficient
(Spearman’s rho) ranging between 0.747 for ethanolamine
( p¼ 0.005) and 0.548 for N-acetylaspartate (NAA, p¼ 0.065).
In contrast, tyramine levels were negatively correlated with
viral load (Spearman’s rho¼0.645, p¼ 0.023).
Differential levels of phenylalanine and tyrosine
are associated with HIV disease and ART
Blood phenylalanine-to-tyrosine ratio has been shown to
increase in HIV-1 infected pateints, which decreased follow-
ing ART (Zangerle et al., 2010). Therefore, in the current
study, we investigated whether similar patterns also exist in
oral washes of ART-naive and ART-experienced HIV-infected
patients. We found that levels of tryptophan and phenylala-
nine tended to increase in ART-naive patients, whereas ty-
rosine levels remained unchanged between ART-naive and
Table 2. Heat Map Display of Differentially Expressed Identifiable Metabolites




Amino acid Alanine and aspartate metabolism N-Acetylaspartate (NAA) 0.32 0.01
Glutamate metabolism Gamma-aminobutyrate (GABA) 0.38 0.17
Glycine, serine, and threonine metabolism Betaine 1.36 0.13
Lysine metabolism Cadaverine 1.67 0.16
Phenylalanine and tyrosine metabolism p-Cresol sulfate 4.46 0.03
Phenylalanine and tyrosine metabolism Phenylalanine 1.39 0.09
Phenylalanine and tyrosine metabolism Tyramine 4.17 0.06
Tryptophan metabolism Indolelactate 2.01 0.16
Tryptophan metabolism Tryptophan 1.95 0.18
Urea cycle; arginine-, proline-, metabolism Arginine 0.65 0.14
Valine, leucine, and isoleucine metabolism Isoleucine 2.45 0.14
Carbohydrate Aminosugars metabolism Fucose 0.45 0.09
Aminosugars metabolism N-Acetylglucosamine 0.33 0.09
Aminosugars metabolism N-Acetylneuraminate 0.42 0.11
Fructose, mannose, galactose, starch, and
sucrose metabolism
Galactose 0.34 0.02






Nucleotide sugars, pentose metabolism Xylose 0.37 0.08
Energy Krebs cycle Fumarate 0.72 0.18




Nucleotide Purine metabolism, adenine containing Adenosine 50-monophosphate (AMP) 3.89 0.10




Peptide Dipeptide Glycyltyrosine 0.71 0.16
Dipeptide Leucylisoleucine 3.89 0.20
Xenobiotics Benzoate metabolism Hippurate 0.73 0.07
Red and green cells indicate a significant increase and decrease, respectively, in the levels of metabolites in HIV group relative to healthy
controls. Overall fold change was calculated using samples from all HIV-infected patients. Our results showed that levels of amino acids and
nucleic acid catabolites were generally elevated, while that of carbohydrates were generally reduced, suggesting active catabolic or
fermentative processes.
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ART-experienced HIV-infected patients (Fig. 3). Fucose levels
also remained similar among the healthy and HIV-infected
patient groups. Furthermore, the oral Phe:Tyr ratio increased in
ART-naive HIV-infected patients (mean SEM¼ 2.58 0.87)
compared with healthy (1.33 0.10, p¼ 0.062) individuals or
ART-experienced patients (1.78 0.30, p¼ 0.441). The oral
Phe:Tyr ratio of ART-experienced patients were similar to that
of healthy individuals ( p¼ 0.792).
Discussion
In the current study, we identified the metabolites present
in the oral cavity of HIV-infected patients, and compared this
metabolomic profile to that of healthy individuals. We also
determined whether changes in the metabolomic profile are
associated with HIV disease and response to ART.
Our results showed differential production of specific me-
tabolites in response to HIV infection. These metabolites in-
cluded those that are common to host and microbes, or known
to be of microbial origin (e.g., p-cresol sulfate, allantoin).
Samples obtained from HIV-infected patients exhibited evi-
dence of heightened activity for several catabolic processes
relative to the healthy controls, especially for those related to
amino acid metabolism. In this regard, levels of tyramine and
p-cresol sulfate (both catabolites of tyrosine), were elevated.
Tyramine is a monoamine decarboxylation product of tyro-
sine that can be formed by fermentation processes (Suzzi and
Gardini, 2003). Metabolism of tyrosine and phenylalanine by
the intestinal flora is known to result in the formation of p-
cresol (Curtius et al., 1976), which is further converted by
cytosolic sulphotransferase into p-cresol–sulfate (Burchell and
Coughtrie, 1997). p-Cresol sulfate is a common component of
blood plasma and urine and is considered a uremia toxin
in the treatment of kidney disease because it is not effi-
ciently removed by dialysis. This metabolite exhibits a pro-
inflammatory effect on unstimulated leucocytes and may
contribute to development of vascular disease in uremic
population (Schepers et al., 2007). The presence of p-cresol
sulfate in oral washes of HIV-infected patients suggests that
these patients may have underlying kidney disease. In this
regard, the prevalence of chronic kidney disease (CKD) in
HIV-infected patients ranges globally between 1.1% and
48.5% (Naicker and Fabian, 2010; Volberding and Deeks,
2010). Consequently, early detection programs to assist in
detecting and managing CKD have been proposed as a way to
provide clinical and cost-effective management of CKD (Katz
et al., 2010). Studies investigating the correlation between oral
p-cresol sulfate and kidney function in HIV-infected patients
are warranted.
Elevated levels were also observed for cadaverine and in-
dolelactate, which are breakdown products of lysine and
tryptophan, repspectively. Cadaverine is a bacterial product
that has been associated with oral pathologies including
periodontal disease and bad breath (Barnes et al., 2009; Levine
et al., 2001; Rosenberg, 2002; Scully et al., 1997; Walters, 1987).
Recently, Shah et al. (2010) showed that cadaverine biosyn-
thesis is crucial for fitness and pathogenesis of Streptococcus
pneumoniae, a common oral pathogen. These investigators
showed that mutants deficient in polyamine biosynthesis
(DspeE or Dcad) or transport genes (DpotABCD) were attenu-
ated in murine models of pneumococcal colonization and
pneumonia either alone or in competition with wild-type
strain. Given these findings, it is possible that elevation of
cadaverine levels in HIV-infected patients in our study may
impact the diversity of the oral microbiome in this patient
population relative to healthy controls. Elevated levels of in-
dolelactate may suggest defects in tryptophan metabolism.
Network analyses revealed the presence of several metab-
olites representing amino acid biosynthesis and carbohydrate
metabolism pathways. Some of these metabolites (e.g., gly-
cine, sorbitol) are involved in overlapping metabolic pro-
cesses, and may represent key regulatory points of the overall
metabolome. These metabolites may also play important roles
in regulating host–microbe interactions. Detailed studies in-
vestigating these processes are warranted.
Our data showed that levels of some amino acids, for ex-
ample, phenylalanine and tryptophan, were consistently ele-
vated in the HIV-infected individuals, whereas others like
tyrosine remained unchanged in the setting of HIV. The in-
crease in levels of phenylalanine may be due to a reduced
activity of the enzyme phenylalanine hydroxylase, which
catalyzes the conversion of Phe to Tyr, and is a rate-limiting
step in the biosynthesis of dopamine. We also found signifi-
cant increase in the levels of sarcosine and other metabolites in
ART-naive patients compared with ART-experienced pa-
tients. Interestingly, Sreekumar et al. (2009) recently identified
sarcosine as a potentially mediator of progression of prostate
cancer. The role of these metabolites in HIV disease progres-
sion needs to be investigated.
Alteration in the levels of amino acids during HIV infection
may impact associated opportunists. For example, oral me-
tabolites (e.g., tryptophan) that affect Candida growth are
likely to impact oral candidiasis, which is among the most
FIG. 1. Network connections with a representative metab-
olite (taurine) present differentially in healthy and HIV-
infected patients, interconnected with other metabolites or
pathways. Data were analyzed using the Metscape plugin in
the open-source Cytoscape software. (Enlarged version of
this figure showing all identified metabolites can be viewed
in Supplemental Fig. SF1. Data used to generate the Cytos-
cape network visualization has been provided as Supple-
mental Table ST2.)
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FIG. 2. Differential Correlation Network (DCN) analysis of significant correlations between paired metabolite differences in
oral wash samples. Correlation differences were calculated for (A) healthy vwersus ART-experienced HIV-infected patients
(red edges), and (B) healthy versus HIV-infected (including ART-naive and -experienced) patients (green edges). Metabolite
differential correlation (edge) is displayed as percentage significant difference. Visualization was created with Cytoscape
(www.cytoscape.org), and the metabolites (nodes) were color coded by their KEGG superpathway. (C) Depicts the number of
interactions between metabolites in sampled obtained from healthy versus ART-experienced HIV-infected patients (red) or
healthy versus HIV-infected (green).
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common opportunistic infections associated with HIV infec-
tion (Costa et al., 2006; Patton et al., 2002). In this regard, several
studies have shown that tryptophan directly influences Candida
growth (in vitro and in vivo) and morphology. The enzyme
indole dioxygenase (IDO) converts tryptophan to picolinic acid
(PLA), which inhibits the yeast–hyphal transition of Candida
(Bozza et al., 2005). Blasi et al. (1993) demonstrated that intra-
peritoneal administration of PLA has a protective effect on mice
intracerebrally infected with lethal doses of C. albicans. Tryp-
tophan has also been reported to modulate the activity of
Candida chorismate mutase (a candidal enzyme) and anyhdrase
enzymes, which regulates Phe-to-Tyr conversion and carbon
utilization, respectively (Bode and Birnbaum, 1991; Bode et al.,
1984; Isik et al., 2009). In addition to its direct effect on Candida,
tryptophan can influence bacteria that are important compo-
nents of the polymicrobial oral milieu. In this regard, Candida
converts Trp to b-indolethanol (IEA) and b-indolelactic acid
(ILA), both of which inhibit the growth of Gram-positive and
Gram-negative bacteria (Narayanan and Rao, 1976). It is pos-
sible that the differential levels of metabolites detected in our
study may be associated with Candida colonization in the
mouth of study participants. However, such association could
not be investigated because the collected samples were not
cultured. Future studies should investigate whether changes in
oral metabolites may be associated with Candida colonization of
the oral cavity.
Several studies have reported that PLA mediates interac-
tions between the host immune cells and fungi by several
mechanisms including modulation of the production of
reactive oxygen species (Diamond et al., 1980), inhibition
of neutrophil-mediated killing of Candida pseudohyphae
(Wagner et al., 1986), inducing the production of interferon-g
(Mucci et al., 2003), and augmenting the anti-Candida ac-
tivity of neutrophils (Abe et al., 2004). In addition, tryp-
tophan catabolites (a mixture of 3-hydroxykynurenine,
3-hydroxyanthranilic acid, and quinolinic acid) increased ex-
pression of Foxp3 mRNA and concomitantly upregulated IL-
10 production in Candida-pulsed T cells (De Luca et al., 2007).
It is possible that changes in oral tryptophan levels and its
regulators like IDO and PLA may be associated with T-cell
function and apoptosis in HIV-infected patients. Detailed
studies are warranted to investigate this potential association.
Tryptophan is converted by microbial aldehyde dehydro-
genase to indole-3-acetic acid (IAA), a plant auxin that has also
been identified in bacteria (Barash and Manulis-Sasson, 2009;
Patten & Glick, 1996) and fungi (Gruen, 1959; Thimann, 1935).
Rao et al. (2010) showed that IAA stimulates filamentation in
C. albicans, thus suggesting a role in Candida pathogenesis.
However, we found that IAA levels remained similar between
the healthy, ART-naive and ART-experienced sample groups
( p 0.234). This lack of a concomitant increase in IAA levels
with tryptophan in the tested samples may be due to the fact
that yeast cells have been shown to synthesize IAA using
both tryptophan-dependent and -independent pathways
(Rao et al., 2010). Further investigation is warranted to ex-
plore the association between tryptophan and host immu-
nity as well as the polymicrobial constituents of the oral
microbiome.
Among the nucleic acids detected, levels of allantoin,
thymine, and AMP were elevated in HIV-infected participants.
Allantoin is produced in most mammals by oxidation of uric
acid in a conversion catalyzed by the peroxisomal enzyme
urate oxidase (or uricase, EC 1.7.3.3), but this enzyme activity is
absent in humans (Varela-Echavarria et al., 1988). Detection of
allantoin in the oral samples analyzed in the current study
suggests the possibly that it is derived from oral microbes. In
this regard, allantoin has been identified as a degradation
product of microbial metabolism of purines and pyrimideins
(Cooper, 1984; Vogels and Van der Drift, 1976). Under nitro-
gen-deprived conditions, yeast can use allantoin as a nitrogen
source and accumulate it in vacuoles as a reserve (Cooper,
1984). Genes involved in nitrogen metabolic regulation (e.g.,
GLN3, a key regulator of allantoin metabolism) have been
suggested to cooperate with multiple positive-acting, pathway-
Table 3. List of Metabolites with Significant Differences in Levels (Relative Abundance, Mean log10 SD)
between ART-Naive and ART-Experienced Patients
Metabolite ART-naı̈ve (Mean SD) ART-experienced (Mean SD) p-Valuea
Aspartate 6.66 0.27 6.17 0.23 0.007
N-acetylaspartate (NAA) 4.80 0.10 4.53 0.14 0.006
Serine 6.51 0.32 6.11 0.22 0.029
Glutarate (pentanedioate) 4.65 0.29 4.06 0.45 0.042
3-Phenylpropionate (hydrocinnamate) 5.81 0.42 4.42 0.64 0.003
Phenylacetate 5.44 0.22 4.65 0.42 0.006
Phenyllactate (PLA) 4.82 0.34 4.38 0.21 0.017
Tyramine 4.59 0.31 5.60 0.57 0.008
Putrescine 7.57 0.32 7.20 0.17 0.022
Indoleacetate 5.61 0.52 4.91 0.45 0.036
5-Aminovalerate 7.11 0.30 6.81 0.13 0.034
Sarcosine (N-Methylglycine) 6.22 0.38 5.83 0.15 0.024
1,5-Anhydroglucitol (1,5-AG) 6.02 0.33 5.58 0.32 0.049
Nicotinate 4.78 0.34 4.39 0.15 0.018
Ethanolamine 6.88 0.46 6.36 0.24 0.025
myo-Inositol 6.35 0.39 5.81 0.33 0.031
scyllo-inositol 5.14 0.63 4.43 0.24 0.016
Glycylproline 5.43 0.36 4.92 0.15 0.005
aFor comparison between ART-naive and -experienced patients.
Data represent relative abundance (log10, mean SD; n¼ 5).
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specific regulatory proteins to turn on specific sets of nitrogen
catabolic genes, and contribute to the pathogenicity of fungal
pathogens (Marzluf, 1997).
All carbohydrate compounds that were significantly dif-
ferent between HIV-infected and healthy subjects were lower
in samples collected from HIV-infected patients. These in-
cluded amino sugars, pyruvate, xylose, and fumarate. Al-
though sucrose levels were significantly different between the
healthy controls and HIV-infected patients, the mean value in
this case was driven strongly by one healthy subject who had
extremely high levels of the compound. Therefore, the high
level of sucrose is unlikely to have any physiological rele-
vance.
Our results showed that oral wash samples obtained from
ART-naive HIV-infected patients exhibited increased oral
Phe:Tyr ratio, which was reduced in ART-experienced pa-
tients to similar levels as seen in healthy subjects. Interest-
ingly, in a recent study, Zangerle et al. (2010) showed that the
Phe:Tyr ratio of serum can be used to monitor immune acti-
vation in cancer and HIV-infected patients. Because we used
oral wash samples in our study, it is possible that this ratio
may have utility in monitoring the immune status (activation)
and/or therapy compliance in HIV-infected patients and their
response to ART by sampling oral wash, which is noninvasive
and presents minimal risks for healthcare workers who
manage these patients. It is also possible that changes in me-
tabolite levels may be linked to viral replication because pa-
tients on ART had low viral loads. Finally, because the
controls in our study were students and staff members from
CWRU School of Dental Medicine and School of Medicine, it
is possible that they had higher awareness and different
practice of dental hygiene than the study group. Controlled
clinical trials need to be performed to assess the association of
changes in oral metabolite levels with these different vari-
ables.
Conclusions
Our metabolomics analysis revealed that oral metabolites
are differentially present in HIV-infected patients, relative to
healthy controls. These studies represent our attempt to begin
addressing the critical gap in knowledge regarding how
changes in the oral metabolome correlate with HIV disease.












































FIG. 3. Levels of representative amino acids and carbohydrates in oral wash samples obtained from healthy and HIV-
infected patients. (A) Tryptophan; (B) fucose; (C) Phenylalanine; (D) Tyrosine.
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their interactions will provide insight into the role of oral
metabolites in HIV-infected patients and the identification of
diagnostic targets.
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